Wei-Wu He - 18 Mar 2026 Form 3 Insider Report for CASI Pharmaceuticals, Inc. (CASIF)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: CASIF
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 19:06:22 UTC
Prior SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Wei-Wu He

Key filing fact

Wei-Wu He filed Form 3 for CASI Pharmaceuticals, Inc. (CASIF) on 18 Mar 2026.

Key facts

This page summarizes Wei-Wu He's Form 3 filing for CASI Pharmaceuticals, Inc. (CASIF).
0 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 19:06.

Change

Previous filing in this sequence was filed on 17 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001542073 Primary reporting owner

He Wei-Wu

Relationship: Director, 10%+ Owner
Address: 1701-1702, CHINA CENTRAL OFFICE TOWER 1,, NO. 81 JIANGUO ROAD CHAOYANG DISTRICT, BEIJING, CHINA
Signature: /s/ Wei-Wu He
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,910,550
Date: 18 Mar 2026
Ownership: Direct

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 44,107
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F1

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 753,234
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F2

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 300,000
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F3

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F4

CASIF holding

Ordinary Share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 637,644
Date: 18 Mar 2026
Ownership: See Footnote
Footnotes: F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CASIF holding Derivative

Convertible Note (right to convert)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: See Footnote
Underlying class: Ordinary Share
Underlying amount
Exercise price
Footnotes: F6, F7

CASIF holding Derivative

Convertible Note (right to convert)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: See Footnote
Underlying class: Ordinary Share
Underlying amount
Exercise price
Footnotes: F6, F7

CASIF holding Derivative

Convertible Note (right to convert)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: See Footnote
Underlying class: Ordinary Share
Underlying amount
Exercise price
Footnotes: F6, F7

CASIF holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Share
Underlying amount: 20,000
Exercise price: $1.93

CASIF holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Share
Underlying amount: 20,000
Exercise price: $1.93

CASIF holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Share
Underlying amount: 100,000
Exercise price: $1.93

CASIF holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Share
Underlying amount: 100,000
Exercise price: $1.93

CASIF holding Derivative

Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Share
Underlying amount: 300,000
Exercise price: $1.93
Footnotes: F8

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 8 footnotes

Footnote F1

Held by Emerging Technology Partners, LLC, a Delaware limited liability company, of which Dr. He is founder and managing partner.

Footnote F2

Held by ETP Global Fund. L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

Footnote F3

Held by ETP BioHealth III Fund, L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

Footnote F4

Held by HE Family GRAT, a grantor retained annuity trust organized under the law of Nevada for the benefit of Dr. Wei-Wu He's family members, and Dr. Wei-Wu He is the trustee of HE Family GRAT.

Footnote F5

Held by Huiying Memorial Foundation, a 501(c)(3) private family foundation under the law of Delaware and Dr. He is a member of the board of trustees and an officer of the Huiying Memorial Foundation. Dr. He does not participate in the investment decisions of the Foundation with respect to CASI's ordinary shares and disclaims beneficial ownership of CASI's ordinary shares held by Huiying Memorial Foundation.

Footnote F6

The conversion price is volume weighted average closing price of the issuer's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. Pursuant to the trading price of the issuer's ordinary shares as of March 17, 2026, the amount of ordinary shares convertible under each Note is 5,000,000 (without considering accrued but unpaid interest).

Footnote F7

Held by ETP Global Fund III L.P., , a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

Footnote F8

Performance based options granted and exercisable upon achievement.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .